NASDAQ:STTK

Shattuck Labs - STTK Stock Forecast, Price & News

$2.19

-0.10 (-4.37%)

(As of 11/28/2022 12:00 AM ET)

Add

Compare

Today's Range: $2.02
▼
$2.32
50-Day Range: $1.96
▼
$3.26
52-Week Range: $1.85
▼
$9.61

Volume: 76,379 shs
Average Volume: 159,005 shs
Market Capitalization: $92.84 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.50

Shattuck Labs MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 744.7% Upside
$18.50 Price Target
Short Interest: Healthy
0.99% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.43) to ($2.20) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

339th out of 1,040 stocks

Pharmaceutical Preparations Industry

153rd out of 509 stocks

3.5

Analyst's Opinion

Consensus Rating
Shattuck Labs has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.50, Shattuck Labs has a forecasted upside of 744.7% from its current price of $2.19.
Amount of Analyst Coverage
Shattuck Labs has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.99% of the float of Shattuck Labs has been sold short.
Short Interest Ratio / Days to Cover
Shattuck Labs has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Shattuck Labs has recently decreased by 8.70%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Shattuck Labs does not currently pay a dividend.
Dividend Growth
Shattuck Labs does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for STTK.

3.8

News and Social Media Coverage

News Sentiment
Shattuck Labs has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Shattuck Labs this week, compared to 1 article on an average week.
Search Interest
4 people have searched for STTK on MarketBeat in the last 30 days.
MarketBeat Follows
2 people have added Shattuck Labs to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Shattuck Labs insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.89% of the stock of Shattuck Labs is held by insiders.
Percentage Held by Institutions
50.59% of the stock of Shattuck Labs is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Shattuck Labs are expected to grow in the coming year, from ($2.43) to ($2.20) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Shattuck Labs is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Shattuck Labs is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Shattuck Labs has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Shattuck Labs (NASDAQ:STTK) Stock

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Receive STTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shattuck Labs and its competitors with MarketBeat's FREE daily newsletter.

STTK Stock News Headlines

November 12, 2022 | seekingalpha.com

Shattuck Labs, Inc. (STTK) Q3 2022 Earnings Call Transcript

November 11, 2022 | finance.yahoo.com

Shattuck Labs Third Quarter 2022 Earnings: US$0.58 loss per share (vs US$0.41 loss in 3Q 2021)

November 8, 2022 | finance.yahoo.com

Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights

November 7, 2022 | msn.com

Preview: Shattuck Labs's Earnings

November 7, 2022 | finance.yahoo.com

Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 4, 2022 | finance.yahoo.com

Investors in Shattuck Labs (NASDAQ:STTK) have unfortunately lost 86% over the last year

November 3, 2022 | finance.yahoo.com

Shattuck Labs Announces Participation in Upcoming November Conferences

November 1, 2022 | finance.yahoo.com

Shattuck Labs to Report Third Quarter 2022 Financial Results on November 8, 2022

October 12, 2022 | finance.yahoo.com

Owning 38% shares,institutional owners seem interested in Shattuck Labs, Inc. (NASDAQ:STTK),

October 5, 2022 | finance.yahoo.com

Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12

September 29, 2022 | nasdaq.com

Shattuck Labs, Inc. (NASDAQ:STTK) is definitely on the radar of institutional investors who own 38% of the company

August 31, 2022 | seekingalpha.com

Shattuck Labs initiated at buy at BTIG on Agonist Redirected Checkpoint platform

August 20, 2022 | finance.yahoo.com

We Think Shattuck Labs (NASDAQ:STTK) Needs To Drive Business Growth Carefully

August 15, 2022 | nasdaq.com

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

August 11, 2022 | msn.com

Recap: Shattuck Labs Q2 Earnings

August 11, 2022 | finance.yahoo.com

Shattuck Labs Reports Second Quarter 2022 Financial Results and Recent Business Highlights

July 19, 2022 | uk.finance.yahoo.com

Shattuck Labs, Inc. (STTK)

July 6, 2022 | finance.yahoo.com

Quite a few insiders invested in Shattuck Labs, Inc. (NASDAQ:STTK) last year which is positive news for shareholders

May 26, 2022 | nasdaq.com

Shattuck Labs Now the Least Expensive vs. Binance Coin This Year

May 13, 2022 | finance.yahoo.com

Should You Buy Shattuck Labs (STTK) Ahead of Earnings?

May 12, 2022 | finance.yahoo.com

Shattuck Labs Reports First Quarter 2022 Financial Results and Recent Business Highlights

May 6, 2022 | finance.yahoo.com

Why Earnings Season Could Be Great for Shattuck Labs (STTK)

May 3, 2022 | seekingalpha.com

STTK, LYEL and MPWR among after hour movers

April 5, 2022 | finance.yahoo.com

Shattuck Labs Announces Participation in Upcoming 21st Annual Needham Virtual Healthcare Conference

April 2, 2022 | apnews.com

Final Deadline Alert: The Schall Law Firm Encourages Investors in Shattuck Labs, Inc. with Losses of $100,000 to Contact the Firm

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive STTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shattuck Labs and its competitors with MarketBeat's FREE daily newsletter.

STTK Company Calendar

Last Earnings: 11/09/2021
Today: 11/28/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/21/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:STTK
CUSIP: N/A
CIK: 1680367
Web: www.shattucklabs.com
Phone: 512-900-4690
Fax: N/A
Employees: 85
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $18.50
High Stock Price Forecast: $28.00
Low Stock Price Forecast: $12.00
Forecasted Upside/Downside: +744.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.63)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-44,970,000.00
Net Margins: N/A
Pretax Margin: -226.32%
Return on Equity: -29.15%
Return on Assets: -26.33%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.53
Quick Ratio: 10.53

Sales & Book Value

Annual Sales: $30.02 million
Price / Sales: 3.09
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.43 per share
Price / Book: 0.34

Miscellaneous

Outstanding Shares: 42,391,000
Free Float: 38,199,000
Market Cap: $92.84 million
Optionable: Not Optionable
Beta: 0.95

Key Executives

Dr. Taylor H. Schreiber M.D. (Age 42)
Ph.D., Co-Founder, CEO & Director
Comp: $744.45k

Dr. Arundathy Nirmalini Pandite M.B.A. (Age 63)
M.D., Chief Medical Officer
Comp: $638.44k

Ms. Casi DeYoung (Age 51)
Chief Bus. Officer
Comp: $523.48k

Mr. Andrew R. Neill M.B.A. (Age 36)
Chief Financial Officer

Conor Richardson
Sr. Director of Fin. & Investor Relations

Dr. Abhinav A. Shukla Ph.D. (Age 49)
Chief Technical Officer

Ms. Erin Ator Thomson J.D. (Age 42)
Gen. Counsel, Corp. Sec. and Chief Ethics & Compliance Officer

Dr. Thomas Lampkin Pharm.D.
Sr. VP of Regulatory Affairs

Ms. Fatima Rangwala M.D.
Ph.D., Sr. VP of Clinical Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

STTK Stock - Frequently Asked Questions

Should I buy or sell Shattuck Labs stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Shattuck Labs in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STTK shares.
View STTK analyst ratings or view top-rated stocks.
What is Shattuck Labs' stock price forecast for 2023?: 4 Wall Street analysts have issued 1 year price objectives for Shattuck Labs' shares. Their STTK share price forecasts range from $12.00 to $28.00. On average, they expect the company's stock price to reach $18.50 in the next year. This suggests a possible upside of 744.7% from the stock's current price.
View analysts price targets for STTK or view top-rated stocks among Wall Street analysts.
How have STTK shares performed in 2022?: Shattuck Labs' stock was trading at $8.51 on January 1st, 2022. Since then, STTK stock has decreased by 74.3% and is now trading at $2.19.
View the best growth stocks for 2022 here.
When is Shattuck Labs' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our STTK earnings forecast.
How were Shattuck Labs' earnings last quarter?: Shattuck Labs, Inc. (NASDAQ:STTK) posted its earnings results on Tuesday, November, 9th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.04. The firm had revenue of $1.90 million for the quarter.

When did Shattuck Labs IPO?: (STTK) raised $150 million in an initial public offering on Friday, October 9th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Evercore ISI acted as the underwriters for the IPO and Needham & Co. was co-manager.
What is Shattuck Labs' stock symbol?: Shattuck Labs trades on the NASDAQ under the ticker symbol "STTK."
Who are Shattuck Labs' major shareholders?: Shattuck Labs' stock is owned by many different institutional and retail investors. Top institutional shareholders include Clark Estates Inc. NY (3.17%), Prosight Management LP (2.64%), BlackRock Inc. (1.78%), Renaissance Technologies LLC (0.63%), Investment Management of Virginia LLC (0.56%) and Benjamin F. Edwards & Company Inc. (0.40%). Insiders that own company stock include Andrew R Neill, Erin Ator Thomson, George Golumbeski, Josiah Hornblower, Redmile Group, Llc, Taylor Schreiber and Tyler Brous.
View institutional ownership trends.
How do I buy shares of Shattuck Labs?: Shares of STTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Shattuck Labs' stock price today?: One share of STTK stock can currently be purchased for approximately $2.19.
How much money does Shattuck Labs make?: Shattuck Labs (NASDAQ:STTK) has a market capitalization of $92.84 million and generates $30.02 million in revenue each year. The company earns $-44,970,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.
How can I contact Shattuck Labs?: The official website for the company is www.shattucklabs.com. The company can be reached via phone at 512-900-4690 or via email at investorrelations@shattucklabs.com.

This page (NASDAQ:STTK) was last updated on 11/28/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial